2001 SCCM/ESICM/ACCP/ATS/SIS International Sepsis Definitions Conference

Critical Care Medicine

Volumn 31, Issue 4, 2003, Pages 1250-1256

  Levy, Mitchell M ^a,j   Fink, Mitchell P ^b   Marshall, John C ^c   Abraham, Edward ^d   Angus, Derek ^b   Cook, Deborah ^e   Cohen, Jonathan ^f   Opal, Steven M ^g   Vincent, Jean Louis ^h   Ramsay, Graham ⁱ  

^a RHODE ISLAND HOSPITAL   (United States)

^b UNIVERSITY OF PITTSBURGH MEDICAL CENTER   (United States)

^c TORONTO GENERAL HOSPITAL   (Canada)

^d UNIVERSITY OF COLORADO   (United States)

^e ST JOSEPH S HOSPITAL   (Canada)

^f Imperial College of Medicine   (United Kingdom)

^g MEMORIAL HOSPITAL OF RHODE ISLAND   (United States)

^h ERASME HOSPITAL   (Belgium)

ⁱ MAASTRICHT UNIVERSITY MEDICAL CENTER   (Netherlands)

^j BROWN UNIVERSITY   (United States)

more..

Author keywords

PIRO; Sepsis; Septic shock; Severe sepsis; Systemic inflammatory response syndrome

Indexed keywords

CLINICAL FEATURE; CONFERENCE PAPER; DIAGNOSTIC PROCEDURE; HUMAN; INTENSIVE CARE; MEDICAL SOCIETY; PATHOPHYSIOLOGY; PRIORITY JOURNAL; SEPSIS; STAGING;

HUMANS; MULTIPLE ORGAN FAILURE; SEPSIS; SHOCK, SEPTIC; SYSTEMIC INFLAMMATORY RESPONSE SYNDROME; TERMINOLOGY;

EID: 0037389094     PISSN: 00903493     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.CCM.0000050454.01978.3B     Document Type: Conference Paper

References (41)

1. Members of the American College of Chest Physicians/Society of Crit Care Med Consensus Conference Committee: American College of Chest Physicians/Society of Crit Care Med Consensus Conference: Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. Crit Care Med 1992; 20:864-874
2. Marshall JC: SIRS and MODS: What is their relevance to the science and practice of intensive care? Shock 2000; 14:586-589
3. Vincent J-L: Dear SIRS, I'm sorry to say that I don't like you. Crit Care Med 1997; 25:372-374
4. Ramsay G, Gerlach H, Levy MM, et al: An international sepsis survey: A Study of doctors' knowledge and perception about sepsis. Crit Care Med 2003; 31:
5. Nomenclature and Criteria for Diagnosis of Ischemic Heart Disease: Report of the Joint International Society and Federation of Cardiology/World Health Organization Task Force on Standardization of Clinical Nomenclature. Circulation 1979; 59:607-609
6. Falahati A, Sharkey SW, Christensen D, et al: Implementation of serum cardiac troponin I as marker for detection of acute myocardial infarction. Am Heart J 1999; 137:332-337
7. Antman EM, Grudzien C, Mitchell RN, et al: Detection of unsuspected myocardial necrosis by rapid bedside assay for cardiac troponin T. Am Heart J 2002; 133:596-598
8. Puleo PR, Meyer D, Wathen C, et al: Use of a rapid assay of subforms of creatine kinase MB to diagnose or rule out acute myocardial infarction. N Engl J Med 2002; 331:561-566
9. Myocardial infarction redefined - A consensus document of The Joint European Society of Cardiology/American College of Cardiology Committee for the Redefinition of Myocardial Infarction. J Am Coll Cardiol 2000; 36:959-969
10. Taniguchi T, Koido Y, Aiboshi J, et al: Change in the ratio of interleukin-6 to interleukin-10 predicts a poor outcome in patients with systemic inflammatory response syndrome. Crit Care Med 1999; 27:1262-1264
11. Ueda S, Nishio K, Minamino N, et al: Increased plasma levels of adrenomedullin in patients with systemic inflammatory response syndrome. Am J Respir Crit Care Med 1999; 160:132-136
12. Stoiser B, Knapp S, Thalhammer F, et al: Time course of immunological markers in patients with the systemic inflammatory response syndrome: Evaluation of sCD14, sV-CAM-1, sELAM-1, MIP-1 alpha and TGF-beta 2. Eur J Clin Invest 1998; 28:672-678
13. Hietaranta A, Kemppainen E, Puolakkainen P, et al: Extracellular phospholipases A2 in relation to systemic inflammatory response syndrome (SIRS) and systemic complications in severe acute pancreatitis. Pancreas 2002; 18:385-391
14. Takala A, Jousela I, Olkkola KT, et al: Systemic inflammatory response syndrome without systemic inflammation in acutely ill patients admitted to hospital in a medical emergency. Clin Sci (Lond) 1999; 96:287-295
15. Sablotzki A, Borgermann J, Baulig W, et al: Lipopolysaccharide-binding protein (LBP) and markers of acute-phase response in patients with multiple organ dysfunction syndrome (MODS) following open heart surgery. Thorac Cardiovasc Surg 2001; 49:273-278
16. Harbarth S, Holeckova K, Froidevaux C, et al: Diagnostic value of procalcitonin, interleukin-6, and interleukin-8 in critically ill patients admitted with suspected sepsis. Am J Respir Crit Care Med 2001; 164:396-340
17. Duflo F, Debon R, Monneret G, et al: Alveolar and serum procalcitonin: Diagnostic and prognostic value in ventilator-associated pneumonia. Anesthesiology 2002; 96:74-79
18. Angus DC, Linde-Zwirble WT, Lidicer J, et al: Epidemiology of severe sepsis in the United States: Analysis of incidence, outcome, and associated costs of care. Crit Care Med 2001; 29:1303-1310
19. Marshall JC, Cook DJ, Christou NV, et al: Multiple organ dysfunction score: A reliable descriptor of a complex clinical outcome. Crit Care Med 1995; 23:1638-1652
20. Ferreira FL, Bota DP, Bross A, et al: Serial evaluation of the SOFA score to predict outcome in critically ill patients. JAMA 2002; 286:1754-1758
21. Wilkinson JD, Pollack MM, Ruttiman, et al: Outcome of pediatric patient with multiple organ system failure. Crit Care Med 1986; 14:271-274
22. Proulx F, Fagan M, Farrell CA, et al: Epidemiology of sepsis and multiple organ dysfunction syndrome in children. Chest 1996; 109:1033-1037
23. Doughty LA, Carcillo JA, Kaplan SS, et al: Plasma nitrite and nitrate concentration and multiple organ failure in pediatric sepsis. Crit Care Med 1996; 109:1033-1037
24. Leteutre S, LaCroix J, LeClerc F, et al: Pediatric Logistic Dysfunction Score. Med Decis Making 1997
25. Carcillo JA, Task Force Members, Fields AI: Clinical Practice Parameters for Hemodynamic Support of Pediatric and Neonatal Patients in Septic Shock. Crit Care Med 2002; 30;1-13
26. Denoix PX: Enquete permanent dans les centres anticancereaux. Bull Inst Natl Hyg 1946; 1:70-75
27. Gospodarowicz M, Benedet L, Hutter RV, et al: History and international developments in cancer staging. Cancer Prev Cont 1998; 2:262-268
28. Renaud B, Brun-Buisson C, ICU-Bacteremia Study Group: Outcomes of primary and catheter-related bacteremia: A cohort and case-control study in critically ill patients. Am J Respir Crit Care Med 2001; 163:1584-1590
29. Opal SM, Cohen J: Clinical gram-positive sepsis: Does it fundamentally differ from gram-negative bacterial sepsis? Crit Care Med 1999; 27:1608-1616
30. Ziegler EJ, Fisher CJ Jr, Sprung CL, et al: Treatment of Gram-negative bacteremia and septic shock with HA-1A human monoclonal antibody against endotoxin: A randomized, double-blind, placebo-controlled trial. N Engl J Med 1991; 324:429-436
31. Wortel CH, von der Mohlen MAM, van Deventer SJH, et al: Effectiveness of a human monoclonal anti-endotoxin antibody (HA-1A) in gram-negative sepsis: Relationship to endotoxin and cytokine levels. J Infect Dis 1992; 166:1367-1374
32. McCloskey RV, Straube RC, Sanders C, et al: Treatment of septic shock with human monoclonal antibody HA-1A: A randomized, double-blind, placebo-controlled trial. Ann Intern Med 1994; 121:1-5
33. Hausfater P, Garric S, Ayed SB, et al: Usefulness of procalcitonin as a marker of systemic infection in emergency department patients: A prospective study. Clin Infect Dis 2002; 34:895-901
34. Damas P, Ledoux D, Nys M, et al: Cytokine serum level during severe sepsis in human IL-6 as a marker of severity. Ann Surg 1992; 215:356-362
35. Panacek EA, Kaul M: IL-6 as a marker of excessive TNF-alpha activity in sepsis. Sepsis 1999; 3:65-73
36. Bernard GR, Vincent J-L, Laterre PF, et al: Efficacy and safety of recombinant human activated protein C for severe sepsis. N Engl J Med 2001; 344:699-709
37. Annane D, Sébille V, Charpentier C, et al: Effect of treatment with low doses of hydrocortisone and Fludrocortisone on mortality in patients with septic shock. JAMA 2002; 288:862-871
38. Vincent J-L, Moreno R, Takala J, et al: The SOFA (Sepsis-related Organ Failure Asessment) score to describe organ dysfunction/failure. Intensive Care Med 1996; 22:707-710
39. Marshall JC, Panacek EA, Teoh L, et al: Modeling organ dysfunction as a risk factor, outcome, and measure of biologic effect in sepsis. Crit Care Med 2001; 28:A46
40. Eli Lilly and Company: Briefing Document for XIGRIS for the Treatment of Severe Sepsis. http:www.fda.gov/ohrms/dockets/ac/01/briefing/3797b1_01_Sponsor.htm, August 6, 2001
41. Cook R, Cook DJ, Tilley J, et al: Multiple organ dysfunction: Baseline and serial component scores. Crit Care Med 2001; 29: 2046-2050